Pathology Report: Subject Name: HELFRICH, PETER

[Guest guest]

Pathology Report

Issued: 11/07/09 ID# MR00035017

Subject Name: HELFRICH, PETER

Specimen #: S-09-18590

Sex: M

Date Collected: 10/27/2009

Date Received: 11/05/2009

Attending Physician: Dr. Pollan,

PMFS Strong Memorial Hospital

601 Elm. Ave. Box 705

Rochester, NY 14642

Specimen Identification: Right Buccal Mucosa, lesion present for unknown period

of time.

Clinical History: Helfrich has been exposed to toxic fungi within his

apartment.

Specimen Description: The specimen, labeled tissue for slide prep documentation

only, consists of two tan-red fragments aggregating to 0.9 x 0.8 x 0.3 cm,

completely submitted in one cassette for slide prep documentation only.

Microscopy: One Specimen

• There is a moderate amount of basket-weave fibrinous inflammation observed on

the mucosal surface in a uniform application.

• There is thickening of the epidermis of between 8-16 cells thick. Normal

thickness of epidermis is 1-3 cells.

• The Buccal biopsy does extend to the full depth of the muscle layer to reveal

the full depth of the fibrin deposition.

• There is hyaline-appearing fibrinous inflammation just beneath the basement

membrane and it continues well into the deep tissue including muscle,

demonstrating the classic fingerprint of moderate chronic exposure of a year in

duration to Trichothecene Mycotoxins.

• Several arteries are partially occluded with fibrinous inflammation or

exudates, which is typical of all arteries of the body, and consistent with

severe poisoning of the Trichothecene Mycotoxins. There are 30 microns of

fibrin deposited within these arteries.

• The fibrinous inflammation is also indicative of ongoing ambient inhalation

exposure to the highly poisonous Trichothecene Mycotoxins. The uniform reaction

observed to the dermis is consistent with fungal vapors of Trichothecene

Mycotoxins.

• Fibrinous inflammation is formed in the body when it is exposed to

Trichothecene Mycotoxins. The fingerprint is highly specific and no other

chemical exposure will cause this.

• The small arteries indicate a severe yeast infection within the systemic

circulation. There is a severe infection of yeast observed within the small

arteries.

• The buccal tissue reveals a strong positive reaction to Trichothecene

Mycotoxins by filling the deep dermis with fibrin. There also is moderate

amount of muscle necrosis observed. This confirms the fact that when Mycotoxins

are present within the tissue, fibrin is also found.

• The stage of progression of this chemical poisoning of Trichothecene

Mycotoxins is evaluated as Late Stage II.

• On examination of the buccal tissue no neoplastic cells were observed.

Diagnosis

The pathology clearly demonstrates severe chronic poisoning for a year in

duration to Late Stage II from exposure to the highly irritating epoxides,

Trichothecene Mycotoxins, via vapors, dermal contact and inhalation, which is

consistent with the formation and progression of the disease called

Trichothecene Mycotoxicosis. There are severe yeast organisms observed within

the small arteries of the buccal tissue.

_________________________________________

A. Croft, DVM, PhD, Medical Pathologist

Significance of Tissue Biopsy

Helfrich clearly demonstrates cellular poisoning to the extent of Late

Stage II in progression of the disease called Trichothecene Mycotoxicosis within

his body. The severity of the fibrinous inflammation in the arteries observed

within the buccal tissue, similar to skin is indicative of the state of the rest

of the arteries within the body. The integumentary (skin) is of substantial

importance and can be used for diagnostic purposes. ,

These highly poisonous epoxide chemicals react systemically, in other words,

with all the body's organs and systems in a generalized diffuse fashion in a

stealth manner. By examination of arteries in one organ, a clear picture is

available of what will be present in other arteries and other organs with the

same extent of damage.

The biology, pathology, and the fingerprint of Trichothecene Mycotoxicosis

resulting from consumption, dermal exposure, and inhalation has been

well-established in humans and animals and has been widely reported , , , ,

in the available medical and scientific literature.

There is significant evidence that points to moderate loss of tissue cells and

fibrinous inflammation of the other major organs and systems: brain, lung,

heart, liver, spleen, kidneys, pancreas and the gastrointestinal,

cardiovascular, skeletal, reproductive, lymphatic and immune systems in humans

after exposure to Trichothecene Mycotoxins. In most cases, the necrosis, or

dead tissue cells from these organs will not be regenerated or replaced.

The reduction and eventual removal of the Trichothecene Mycotoxins that caused

fibrinous inflammation indicating Mycotoxin exposure is of the utmost importance

in the therapeutic approach of patients with this level of progression of the

disease. In cases of continued exposure to the Trichothecene Mycotoxins the

intestinal mucosa cannot regenerate and will slough leading to the starvation of

the patients. Patients should be made aware of this health condition and

attempt to remove themselves from contaminated environments. At this stage in

the disease, without treatment of the affected systems, the prognosis is poor,

and with therapy the prognosis is guarded to good. Major efforts must also be

made to control yeast infection within the body, which is consistent with

Trichothecene Mycotoxin exposure.

THERAPY: Treatment of fibrinous inflammation can only be accomplished under a

strict set of controlled conditions:

• Controlled environment that is totally free of Mycotoxins.

• Rehabilitative therapy using nutritive means.

• Monitor patient for fungal infection and yeast infection due to the severe

immune depression.

• The patient should also be watched and monitored for development of cancer

within the following organs: brain, spinal column, respiratory system, liver,

spleen, kidney, urinary bladder, lymph nodes, thyroid, parathyroid, hormonal

glands, including pituitary gland, gastrointestinal system, reproductive system

including breast, pancreatic, skeletal, muscle and skin.

• Helfrich is 33 years of age. The LD-50 (lethal dose at 50%) of

Trichothecene Mycotoxins is 500 parts per billion/kg. The patient's exposure

can be computed by dividing the patient's weight (138 lbs) by 2.2 pounds, will

yield 62.7 kg, and multiply that times 90 ppb/kg will yield 5.6 mg, Daryl Stasky

exposure to the highly poisonous epoxide chemicals, Trichothecene Mycotoxins, at

minimum levels.

• In laboratory rats 500 parts per billion/kg deposited 20-21 microns of fibrin

within the small arteries. Helfrich expressed 30 microns of fibrin

deposition or equal to 500 ppb/kg or 44.76, Helfrich's exposure to

Trichothecene Mycotoxins on a pathological level. That amount of Trichothecene

Mycotoxins is highly significant biologically1-8 and puts Helfrich in

Late Stage II of this disease.

Conclusion

It is my opinion to a reasonable degree of pathologic, scientific and medical

certainty that the ingestion, dermal exposure and inhalation of Trichothecene

Mycotoxins by Helfrich has caused a high number of adverse health effects

to the central nervous system, brain, spinal cord, peripheral nervous system,

skeletal, respiratory, cardiovascular, digestive, hepatic, pancreatic, renal,

reproductive, lymphatic and immune systems and remaining systems.

It is my opinion to a reasonable degree of scientific and pathologic certainty

that the available scientific and medical peer-reviewed publications, research

literature and studies relating to the adverse and toxic health effects caused

by inhalation, dermal exposure and ingestion of Mycotoxins are reliable and

widely accepted in their relevant scientific and medical communities.

The opinions I have expressed in this case conform to the current body of

peer-reviewed scientific and medical literature, which is generally accepted as

reliable in both the scientific and medical communities.

______________________________________________

A. Croft, DVM, PhD, Medical Pathologist

WAC/kmg